Addex Therapeutics Ltd
ADXN8.000USD
-0.380-4.53%
Cierre 12/24, 13:00（ET）Cotizaciones retrasadas 15 min
7.77MCap. mercado
PérdidaP/E TTM
Más Datos de Addex Therapeutics Ltd Compañía
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Información de Addex Therapeutics Ltd
Símbolo de cotizaciónADXN
Nombre de la empresaAddex Therapeutics Ltd
Fecha de salida a bolsaMay 22, 2007
Director ejecutivoDyer (Tim)
Número de empleados2
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 22
DirecciónChemin des Mines, 9
CiudadPLAN-LES-OUATES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal1202
Teléfono41228841555
Sitio Webhttps://www.addextherapeutics.com/en/
Símbolo de cotizaciónADXN
Fecha de salida a bolsaMay 22, 2007
Director ejecutivoDyer (Tim)
Ejecutivos de Addex Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Dr. Roger G. Mills
Dr. Roger G. Mills
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
GAMMA Investing LLC
0.01%
Otro
99.99%
Accionistas
Accionistas
Proporción
GAMMA Investing LLC
0.01%
Otro
99.99%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
0.01%
Otro
99.99%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
11
199.00
18.66%
--
2025Q3
13
199.00
18.82%
-178.00
2025Q2
13
377.00
18.92%
-12.73K
2025Q1
16
13.11K
17.74%
-176.53K
2024Q4
18
15.10K
16.53%
+13.71K
2024Q3
23
37.43K
17.28%
-1.01K
2024Q2
22
38.45K
22.31%
+2.01K
2024Q1
21
36.44K
17.06%
-145.91K
2023Q4
20
195.87K
5.59%
+122.48K
2023Q3
19
73.39K
85.88%
+23.16K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
GAMMA Investing LLC
121.00
0.01%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
72.00
0.01%
--
--
Jun 30, 2025
SBI Securities Co., Ltd.
5.00
0%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
--
0%
-4.00
-100.00%
Dec 31, 2023
Citadel Advisors LLC
--
0%
-11.74K
-100.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
100.00
0.01%
--
--
Jun 30, 2025
J. Stern & Co. LLP
--
0%
-107.83K
-100.00%
Mar 31, 2024
Armistice Capital LLC
--
0%
-43.00K
-100.00%
Mar 31, 2024
New Enterprise Associates (NEA)
--
0%
-9.00K
-100.00%
Mar 31, 2024
Adar1 Capital Management LLC
--
0%
-1.00K
-100.00%
Dec 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Fecha
Tipo
Relación
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Oct 06, 2023
Merger
20→1
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Addex Therapeutics Ltd?
Los cinco principales accionistas de Addex Therapeutics Ltd son:
GAMMA Investing LLC posee 121.00 acciones, lo que representa el 0.01% del total de acciones.
Rhumbline Advisers Ltd. Partnership posee 72.00 acciones, lo que representa el 0.01% del total de acciones.
SBI Securities Co., Ltd. posee 5.00 acciones, lo que representa el 0.00% del total de acciones.
UBS Financial Services, Inc. posee 0.00 acciones, lo que representa el 0.00% del total de acciones.
Citadel Advisors LLC posee 0.00 acciones, lo que representa el 0.00% del total de acciones.
GAMMA Investing LLC posee 121.00 acciones, lo que representa el 0.01% del total de acciones.
Rhumbline Advisers Ltd. Partnership posee 72.00 acciones, lo que representa el 0.01% del total de acciones.
SBI Securities Co., Ltd. posee 5.00 acciones, lo que representa el 0.00% del total de acciones.
UBS Financial Services, Inc. posee 0.00 acciones, lo que representa el 0.00% del total de acciones.
Citadel Advisors LLC posee 0.00 acciones, lo que representa el 0.00% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Addex Therapeutics Ltd?
Los tres principales tipos de accionista de Addex Therapeutics Ltd son:
GAMMA Investing LLC
Otro
GAMMA Investing LLC
Otro
¿Cuántas instituciones poseen acciones de Addex Therapeutics Ltd (ADXN)?
A fecha de 2025Q4, 11 instituciones poseen acciones de Addex Therapeutics Ltd, con un valor de mercado combinado de aproximadamente 199.00, lo que representa el 18.66% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.16%.
¿Cuál es la mayor fuente de ganancias de Addex Therapeutics Ltd?
El --, el segmento empresarial -- generó la ganancia más alta para Addex Therapeutics Ltd, ascendiendo a -- y representando el --% de la ganancia total.
